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A B S T R A C T
Background: Numerous publications describe the clinical manifestations of post-acute sequelae of SARS-CoV-
2 (PASC or “long COVID”), but they are difficult to integrate because of heterogeneous methods and the lack
of a standard for denoting the many phenotypic manifestations. Patient-led studies are of particular impor-
tance for understanding the natural history of COVID-19, but integration is hampered because they often use
different terms to describe the same symptom or condition. This significant disparity in patient versus clini-
cal characterization motivated the proposed ontological approach to specifying manifestations, which will
improve capture and integration of future long COVID studies.
Methods: The Human Phenotype Ontology (HPO) is a widely used standard for exchange and analysis of phe-
notypic abnormalities in human disease but has not yet been applied to the analysis of COVID-19.
Funding: We identified 303 articles published before April 29, 2021, curated 59 relevant manuscripts that
described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped
287 unique clinical findings to HPO terms. We present layperson synonyms and definitions that can be used
to link patient self-report questionnaires to standard medical terminology. Long COVID clinical manifestations are
not assessed consistently across studies, and most manifestations have been reported with a wide range of syno-
nyms by different authors. Across at least 10 cohorts, authors reported 31 unique clinical features corresponding
to HPO terms; the most commonly reported feature was Fatigue (median 45.1%) and the least commonly
reported was Nausea (median 3.9%), but the reported percentages varied widely between studies.
Interpretation: Translating long COVID manifestations into computable HPO terms will improve analysis, data
capture, and classification of long COVID patients. If researchers, clinicians, and patients share a common lan-
guage, then studies can be compared/pooled more effectively. Furthermore, mapping lay terminology to HPO
will help patients assist clinicians and researchers in creating phenotypic characterizations that are computa-
tionally accessible, thereby improving the stratification, diagnosis, and treatment of long COVID.
Funding: U24TR002306; UL1TR001439; P30AG024832; GBMF4552; R01HG010067; UL1TR002535;
K23HL128909; UL1TR002389; K99GM145411.









Evidence before this study
A majority of survivors of COVID-19 report manifestations that
persist beyond the acute illness, so-called Post-Acute Sequelae of
SARS-CoV-2 (PASC, or “long COVID”). Long COVID can affect
even those whowere initially mildly symptomatic or asymptom-
atic, may include a constellation of neurological, respiratory, car-
diovascular, and gastrointestinal symptoms, and is debilitating
in some affected individuals. Research on long COVID has been
complicated due to heterogeneous study methods and lack of a
standard for denoting the many phenotypic manifestations (dif-
ferent terms to describe the same symptom or condition).
Added value of this study
We reviewed 303 manuscripts flagged as relevant to long
COVID by CoronaCentral. From these, we identified 59 manu-
scripts with 81 cohorts that described 287 clinical manifesta-
tions of long COVID. Descriptions (symptoms, laboratory
findings, imaging results) were mapped to Human Phenotype
Ontology (HPO) terms. We have developed layperson syno-
nyms and definitions for each of the 287 HPO terms, which sig-
nificantly improves patient and clinician accessibility.
Implications of all the available evidence
One of the challenges in characterizing long COVID is the fact
that patient-reported symptoms are often not captured by clin-
ical evaluation or in surveys. To truly characterise long COVID
and therefore stratify patients into subtypes for care decisions,
it is necessary to use shared terminology. This common set of
HPO definitions will promote integration of research by trans-
lating between patient and clinician descriptions of symptoms.
We anticipate that this will be a critical resource for use in sur-
vey instruments and patient apps for standardizing patient-
reporting in the future study of long COVID.
1. Introduction
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
emerged in late 2019 as the third human coronavirus identified in
the 21st century. Coronavirus disease 2019 (COVID-19) affects
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diverse organ systems, including the lungs, digestive tract, kidneys,
heart, and brain [1,2]. As of mid-2021, the full spectrum of the clinical
consequences of COVID-19 is not completely understood. Individual
symptoms and disease severity vary widely among patients during
the acute infection, with some patients developing only mild symp-
toms or even remaining asymptomatic. In contrast, others experience
acute respiratory distress syndrome (ARDS), sepsis, and other life-
threatening conditions [3,4]. As more information about patient
recovery has been collected, it has become clear that a wide range of
outcomes can also emerge following the acute phase of the illness,
with some patients experiencing residual symptoms or developing
new symptoms long after the initial infection. This post-acute infec-
tion, referred to as long COVID, post-acute sequelae of COVID (PASC),
or post-acute COVID-19 syndrome (PACS), represents a significant
challenge for patients, physicians, and society because the causes,
patient profile, and even symptom patterns remain difficult to char-
acterise [5]. These substantial challenges in describing long COVID
have led patients to self-organise and perform research to try to
expedite the characterization of this disease and therefore how to
best ameliorate the substantial impact that long COVID has had on
their lives [6].
Long COVID, a multisystem disease, can occur following either
severe, mild, or even asymptomatic SARS-CoV-2 infection [7]. There
is currently no accepted definition of long COVID; however, it can be
broadly defined as delayed recovery from infection with SARS-CoV-2.
Long COVID can occur following cases of COVID-19 that were man-
aged in either inpatient or outpatient settings. It is characterised by
lasting effects of the infection, unexplained persistence of symptoms,
or onset of new chronic diseases, for far longer than would be
expected based on typical rates of viral clearance [8].
Given long COVID’s recent emergence, no standard framework
has yet been established for identifying and assessing associated
symptoms or other clinical features. Furthermore, symptoms fre-
quently reported by long COVID patients are not assessed consis-
tently across studies. A systematic review available as a preprint
evaluated all research on long COVID released prior to January 1,
2021 that included at least 100 patients. Based on the 15 studies that
met the inclusion criteria, the authors identified 55 symptoms of long
COVID [5](preprint). None of the most common symptoms were
assessed by all 15 studies. The authors concluded that the symptoms
of long COVID are extremely heterogeneous and that the assessment
of these symptoms varies widely among studies. Another recent sys-
tematic review concluded that 73% of individuals who had acute
COVID-19 experienced at least one persistent symptom [9]. However,
the authors of the review concluded that the wide variation in design
and quality of the studies limited the direct comparability and com-
binability of the data [9]. The wide range of symptoms attributed to
long COVID are highlighted by an extensive patient-led survey
(Patient-Led Research Collaborative). This study conducted deep lon-
gitudinal characterization of the long COVID symptoms and trajecto-
ries in suspected and confirmed COVID-19 patients who reported
illness lasting more than 28 days [6]. Evaluating data from 3,762
respondents to 257 survey questions, this analysis documented 205
phenotypic features associated with long COVID. The fact that this
patient-led study characterised 205 phenotypic features, while the
studies cited in the aforementioned systematic review reported only
84 signs or symptoms and 19 laboratory or imaging measurements
[9], suggests that the research community has not yet characterised
the full spectrum of clinical manifestations of long COVID. This signif-
icant disparity in patient versus clinical characterization motivates
the proposed ontological approach to specifying manifestations,
which will improve capture and integration of future long COVID
studies.
Deep phenotyping is the precise and comprehensive analysis of
individual phenotypic abnormalities, with a focus on computational
accessibility. In the field of rare disease, the Human Phenotype
Ontology (HPO) has become an international standard for deep phe-
notyping that enables integrated computational analysis of genotype
and phenotype for diagnostics, novel disease gene discovery, and
translational research [10,11]. The HPO includes a standardised
vocabulary of over 16,000 terms with 37,072 synonyms that define
phenotypic abnormalities associated with over 7,000 diseases. This
tool enables non-exact matching of sets of phenotypic features (phe-
notype profile) against known diseases, other patients, and model
organisms. The algorithms have been implemented for computa-
tional comparison of abnormalities and for use in genetic disease
diagnostics, and they are the de facto standard for deep phenotyping
in the field of rare disease. The HPO is used in a range of projects
including the UK’s National Institute for Health Research (NIHR) Rare
Disease initiatives, the 100,000 Genomes project, the NIH Kidney Pre-
cision Medicine Project, and the NIH Undiagnosed Diseases Project
and Network, RD-CONNECT, SOLVE-RD, and many others [10,12].
Existing publications on the clinical aspects of long COVID have not
used a standard vocabulary to report phenotypic abnormalities,
impeding the search, analysis, and integration of information rele-
vant to long COVID in databases such as Medline. Ontologies such as
HPO are systematic representations of knowledge that define termi-
nology in a human-readable format and define relationships between
concepts in a way that allows computational logical reasoning that
supports the integration and analysis of large amounts of data [13].
The significant disparity in patient versus clinical characterization
motivated the proposed ontological approach to specifying manifes-
tations, which will improve capture and integration of future long
COVID studies.
2. Methods
We searched for publications on long COVID using CoronaCentral,
which uses machine learning to process the literature on SARS-CoV-2
[14]. We retrieved 303 articles predicted to be relevant to long COVID
on April 29th, 2021. From these, 59 articles described the clinical
manifestations in clinical cohorts of individuals three weeks or more
following acute COVID-19. We defined three weeks or more based on
the initial appearance of symptoms for outpatients or on three weeks
or more after discharge for hospitalised patients. Descriptions of long
COVID manifestations were mapped to Human Phenotype Ontology
(https://hpo.jax.org/app/) terms. For this study, the HPO release
2021-06-08 was used. Four curators, one with experience in long
COVID and three with extensive experience in HPO curation, manu-
ally reviewed the articles and identified HPO terms that corre-
sponded to the description of clinical abnormalities (symptoms,
signs, laboratory abnormalities, abnormal imaging findings) in the
articles (Figure 1) and mapped them in a spreadsheet. Each mapping
was reviewed by all four curators and discrepancies were resolved
through discussion until consensus was reached. Some publications
described multiple time points (e.g., early and late), or varying severi-
ties of acute illness (e.g., critical/severe, moderate, mild), which were
treated as separate cohorts for the purposes of the current descriptive
analysis (Supplemental Table S1). We tabulated the relationships
between publications and the symptoms they reported, the mapped
HPO terms, and body systems (Supplemental Table S2).
The funders had no role in study design, data collection, data anal-
yses, interpretation, or writing of report.
3. Results
We reviewed 303 articles that were predicted to be relevant to
long COVID. We excluded articles that were reviews, related only to
acute-COVID timepoints, or did not provide sufficient details to
extract percentages for the symptoms (i.e., only provided averages
but not the number of patients affected in a cohort). Analysis of the
remaining 59 articles revealed a variety of criteria were used to
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identify and evaluate patients with long COVID. The studies included
11 cohorts of patients who had been treated in the intensive care
unit (ICU) during acute COVID-19, 36 cohorts of patients who were
hospitalised but not admitted to an ICU during the acute phase, 16
cohorts of patients who were not hospitalised during the acute phase,
and 19 mixed cohorts. Some articles pulled data from electronic
health records (EHRs), while others strictly relied on patient-reported
symptoms from surveys. Studies also varied in the method of collec-
tion and instruments used. Methods of collecting data came from
phone or electronic surveys, in person review, or pull from electronic
medical records. For 26 cohorts, information was collected by in-per-
son, telephone, email, or other online questionnaire. For 51 cohorts,
information was collected by clinical examination, and for 5 cohorts,
information was collected by questionnaire and clinical examination
(Supplemental Table S1). The time frame for data collection and fol-
low-up also differed across studies. Some used a relatively precise
window for patient assessment (e.g., 21 days after symptom onset),
while others included participants at various distances from acute
SARS-COV-2 infection. Some studies aimed to collect information
only on patients suffering from long COVID, while others collected
follow-up information on all patients that had previously had COVID-
19 regardless of whether they currently or ever experienced long
COVID. Studies differed in how they referred to the phenomenon
studied. Some referred to it as long COVID or using a similar term
such as post-acute COVID-19 syndrome, whereas others discussed
the clinical course or patient recovery without mentioning long
Figure 1. The HPO is arranged in a hierarchy from general to more specific. This graph shows a representative hierarchy of a portion of the HPO ‘abnormality of the respiratory sys-
tem’ branch. In this study, observations from 59 publications were mapped to the corresponding HPO terms (nodes). A selection of the original terminology used in the manuscripts
(in italics) is shown adjacent to the HPO term to which it was mapped. A detailed list of all mapped terms is provided in Supplemental File 2.
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COVID specifically. Finally, studies varied widely in the terminology
used to describe patient-reported symptoms.
In the 59 publications and 81 cohorts curated for this study (Sup-
plemental Figure S1), a total of 287 phenotypic abnormalities were
identified and represented as HPO terms. Of these, 132 terms were
used in only one cohort (24.2%), 51 in two cohorts (9.4%), and 62
terms in at least 5 cohorts (21.6%). In most cases, multiple synonyms
were mapped to the same HPO term; for instance, Hepatic steatosis
(HP:0001397) corresponded to four descriptions used in the litera-
ture (Steatosis, Liver steatosis, Fatty infiltration of liver, Fatty liver).
Among terms reported in at least 10 cohorts (n=31 terms), the most
commonly reported feature was Fatigue (median 45.1%), and the least
commonly reported was Nausea (median 3.9%), but the reported per-
centages varied widely between studies (Figure 2).
Full curation details are available in Supplemental File 2. Supple-
mental Figures S2-S26 provide an overview of the 287 phenotypic
features arranged by category, and Supplemental Note 1 provides
additional commentaries. Table 1 provides details on the vast hetero-
geneity of symptoms, organised by the organ systems that are likely
to be involved. Few studies of long COVID to date have conducted
analyses elucidating the presence or extent of organ damage. How-
ever, preliminary investigations of a number of organ systems have
identified organ damage in long COVID patients. These findings are
important because they highlight the possibility of asymptomatic
long COVID patients sustaining organ damage due to the SARS-CoV-2
virus that does not immediately present with symptoms. Therefore,
an improved understanding of organ damage as an outcome of acute
COVID-19 or as a long-term sequelae of the SARS-CoV-2 virus may
present new options for patients experiencing persistent symptoms
or elucidate new information about how the SARS-CoV-2 virus inter-
acts with a range of organ systems.
In our study, we curated 287 HPO terms representing clinical
abnormalities observed in individuals following COVID-19. More
research will be needed to determine which of the terms, and poten-
tially which additional terms, are specifically and causally related to
SARS-CoV-2 infection. For instance, 10 phenotypic abnormalities in
our study have also been reported to occur in Post-Intensive Care
Syndrome (PICS). While most of the manifestations were reported to
Figure 2. Reported frequencies for the 25 phenotypic features identified in 12 or more cohorts. Box plots are shown for each item, displaying the minimum (1.5 times the interquar-
tile range below the lower quartile), first quartile, median, third quartile, and maximum (1.5 times the interquartile range above the upper quartile). Outliers are shown as dots.
DLCO: diffusing capacity of the lungs for carbon monoxide, FEV1: forced expiratory volume in one second; TLC: total lung capacity.
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occur at similar frequencies, Dyspnea was more commonly reported
in patients following COVID-19 (Supplemental Figure S26). Addi-
tional comments are provided in Supplemental Note 2. It is conceiv-
able that in some cases, the occurrence of these ten manifestations in
COVID-19 patients is related to care in the ICU. However, all ten
symptoms have also been reported in cohorts of individuals treated
for COVID-19 as outpatients (Supplemental File 2).
4. Discussion
The fact that some COVID-19 patients experience symptoms fol-
lowing recovery from acute infection is not unexpected. Other infec-
tious diseases, including Epstein-Barr Virus, Giardia lamblia, Coxiella
burnetii, Borrelia burgdorferi (Lyme disease) and Ross River virus are
also associated with an increased risk for post-infectious sequelae.
These sequelae include symptoms such as disabling fatigue, musculo-
skeletal pain, neurocognitive difficulties, and mood disturbance
[1517]. Chronic fatigue syndrome (CFS) is frequently preceded by a
viral infection [18]. However, although these sequelae are well docu-
mented, they are still not well understood, and the molecular mecha-
nisms underlying these post-acute presentations have yet to be
elucidated.
Post-infectious sequelae have also been documented following
infection by other coronaviruses. A subset of patients with severe
acute respiratory syndrome (SARS), caused by the coronavirus SARS-
CoV, and Middle-Eastern Respiratory Syndrome (MERS), caused by
the coronavirus MERS-CoV, were observed to experience persistent
or new-onset symptoms, including fatigue [19], following recovery
from the acute infection [1921]. For SARS, follow-up has been con-
ducted up to 15 years post-infection. In addition to fatigue, studies
reported effects on lung health and capacity [2225], psychological
health [19], bone health [25], and lipid metabolism [26], with the lat-
ter two attributed to treatments involving large doses of steroids
[25,26]. Most of the improvement among SARS patients occurred
within the first one to two years following infection [25,27,28]. Some
patients continued to experience decreased quality of life for more
than a decade following the acute illness [26]. Though follow-up
studies in MERS patients are sparse, effects on pulmonary function
were observed at one year post-infection, with patients who experi-
enced more severe disease at greater risk for long-term effects [29].
Long-term consequences of COVID-19 comprise an unprece-
dented range of clinical abnormalities that we are barely beginning
to understand. These symptoms appear to arise from
pathophysiologic changes that span many organ systems and tissues,
potentially explained by SARS-CoV-2’s interaction with the endothe-
lium [30]. A wide range of outcomes following acute COVID-19 have
emerged as more information about patient recovery has been col-
lected and pathophysiologic mechanisms are revealed. Some patients
experience residual symptoms and others develop new symptoms
long after the initial infection. Given the timeline of SARS-CoV-2’s
emergence, studies to date have tracked patients’ clinical course up
to six months post-infection [3133], but anecdotal reports are avail-
able describing patients with ongoing symptoms as long as one year
post-infection [34]. Symptoms experienced after the acute illness
represent a significant challenge for patients, physicians, and society
as a whole. The causes, patient profile, and even symptom patterns
associated with long COVID remain difficult to isolate, and the natural
history of this condition remains uncharacterised. Goals of research
on long COVID include understanding the natural history of the dis-
ease including the prognosis of the many individual manifestations
of disease, whether there are well delineated subtypes, whether spe-
cific characteristics of the acute phase of COVID-19 predispose to
long COVID, and what treatments may best accelerate recovery. Here,
we have reported 287 HPO terms representing clinical anomalies
reported as long COVID in persons following acute COVID-19. For
some of the terms, such as those reported only once to date, further
research will be required to determine if the abnormalities are specif-
ically related to COVID-19 and their frequency. We have presented
plain-language ‘translations’ of all terms that can be used to create
patient questionnaires.
4.1. Linking layperson and health-professional research
One of the challenges in characterizing long COVID is the fact that
patients report symptoms that may not be captured by clinical evalu-
ation or in standard surveys. To truly characterise long COVID and
therefore stratify patients into subtypes for care decisions, it is neces-
sary to engage patients directly in the description of their long COVID
features. However, medical terminology is often perplexing to
patients, making it difficult for patient-researchers to use resources
like the HPO. Patients themselves are an eager and untapped source
of accurate information about symptoms and phenotypes, some of
which may go unnoticed by the clinician [6]. Patients and clinicians
use different terms to describe the same symptoms or conditions. In
many cases, the clinical term is an exact match to the layperson syno-
nym; however, other times the layperson terminology is less precise.
Table 1
Overview of abnormal phenotypic findings by category. The most commonly reported findings are shown for each category. The total number of features reported in each
organ system is shown in the second column. Categories with at least 7 features are shown. The median percent column shows the median for the percentage of patients
with the feature indicated in the previous column, together with the number of cohorts reporting the feature. Supplemental File S2 provides details.
Category Total reported features Most commonly reported feature Median Percent (number of cohorts)
abnormalities of smell and taste 7 Anosmia (HP:0000458) 12.8% (n=44)
behavioral abnormalities 17 Anxiety (HP:0000739) 22.2% (n=24)
cardiovascular findings 16 Hypertension (HP:0000822) 20.4% (n=4)
cognitive dysfunction 8 Cognitive impairment (HP:0100543) 18.6% (n=13)
dermatological findings 10 Alopecia (HP:0001596) 18.8% (n=9)
emotion/mood abnormalities 9 Depression (HP:0000716) 21.1% (n=25)
gastrointestinal findings 9 Hepatic steatosis (HP:0001397) 26.5% (n=2)
gastrointestinal symptoms 10 Diarrhea (HP:0002014) 3.8% (n=29)
general symptoms 23 Fatigue (HP:0012378) 45.1% (n=48)
laboratory abnormalities 23 Elevated circulating D-dimer concentration (HP:0033106) 26.0% (n=6)
neuropsychiatric findings 30 Dysphagia (HP:0002015) 1.0% (n=7)
ocular abnormalities 13 Blurred vision (HP:0000622) 9.7% (n=7)
pain 9 Myalgia (HP:0003326) 13.8% (n=36)
pulmonary findings 16 Decreased DLCO (HP:0045051) 31.5% (n=18)
pulmonary imaging findings 15 Parenchymal consolidation (HP:0032177) 16.8% (n=8)
reproductive, genitourinary, endocrine,
or metabolism findings
18 Fever (HP:0001945) 0.8% (n=29)
respiratory symptoms 14 Dyspnea (HP:0002094) 35.1% (n=56)
sleep impairment 7 Insomnia (HP:0100785) 31.9% (n=12)
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HPO allows layperson synonyms to be mapped to an ontology, with
more specific terms being defined as subtypes of more general terms.
Mapping lay terminology to HPO for long COVID symptoms will help
patients assist clinicians and researchers in creating robust computa-
tional phenotype profiles, which may improve the diagnosis and
treatment of long COVID. Here, we systematically abstracted 287
long COVID manifestations including signs, symptoms, and labora-
tory as well as imaging abnormalities, added layperson synonyms
where missing, and mapped layperson to HPO terminology. We
wrote plain-language definitions for these terms to supplement the
existing definitions that are aimed at healthcare professionals and
researchers. [35](35). A full list is available in the supplemental mate-
rial in human and computer readable form. This common set of defi-
nitions can promote integration of research by translating between
patient and clinician descriptions of symptoms. We anticipate that
these terms, synonyms and definitions will be a critical resource for
use in survey instruments and patient apps for standardizing patient-
reporting in the future study of long COVID.
In addition to using different terms, inaccurate terms have also
been used to describe some symptoms of long COVID. For example,
“loss of smell” is a commonly reported problem facing patients dur-
ing both acute infection and long COVID. However, this term is often
used to describe both true “loss of smell”, anosmia, and also mistak-
enly used for “distorted smell,” or parosmia. Parosmia is a qualitative
disorder of smell that is defined by distorted olfactory perception in
the presence of an existing stimulus [36]. Parosmia in COVID-19 has
been reported as an unpleasant perception of odorants (troposmia)
that follows anosmia and may persist for several months [37]. Post-
viral parosmia has been suggested to develop in the olfactory neuron
regeneration phase due to a preponderance of immature neurons
during re-innervation [38]. This concept has been proposed for
COVID-19 related parosmia as well due to a similar pattern of succes-
sion [39]. Parosmia was not specifically noted in the studies reviewed
for this work, but has been shown to have a high prevalence in acute
and post-acute COVID-19 associated parosmia [40].
The HPO layperson synonym mapping from this study will facili-
tate the construction of common data elements related to long COVID
research. A strategic plan of the National Library of Medicine (NLM)
2017-2027 and a recent NIH strategic plan for data science identify
common data elements as a means by which to improve data inter-
operability across studies [41]. Developing a standardised vocabulary
with HPO mapped to layperson terms to characterise long COVID
symptoms and findings will provide valuable guidance in building
common data elements for textual and imaging annotation schema
as well as creating patient-centered measurement instruments and
clinical surveys.
As long COVID related data increasingly accumulates in EHRs, it is
promising to generate practice-based evidence through the second-
ary use of EHR. However, it is challenging to conduct such research
without using natural language processing (NLP), since much infor-
mation is only stored in unstructured clinical narratives; additionally,
because many providers are unfamiliar with the vast array of long
COVID symptoms, many are not recorded in these narratives. The lay-
person definitions and associated synonym mapping would greatly
accelerate the development and evaluation of NLP algorithms for
extracting long COVID signs and symptoms from EHRs. Baseline NLP
algorithms based on HPO can be implemented. Specifically, a fast trie
based string matching approach can spot long COVID terms on the fly
in massive clinical corpora for near real-time interactive analyses of
long COVID phenomena from EHR data. A many-to-one mapping
from synonyms to HPO terms identified in this effort will then facili-
tate more rapid long COVID analytics. Additionally, this effort would
enable the rapid development of an annotation guideline for generat-
ing benchmarking data, a critical component in developing and eval-
uating NLP algorithms. If this annotation includes notes from several
sites, even spelling mistakes (that nevertheless refer to long COVID
terms) can be spotted by first building a named entity recognition
(NER) tool and then mapping mentions to long COVID HPO terms
through approximate matching via neural word embeddings con-
structed from character-based neural language models. Another
important affordance of this effort is to be able to mine social media
posts for long COVID disclosures from patients and healthcare con-
sumers to complement EHR-derived surveillance [42](preprint).
As the National COVID Cohort Collaborative (N3C) established a
collaboration among multiple organizations through pandemic data
sharing, i.e., Common Data Model (CDM), the long COVID concept
standardization enabled by this study will play an indispensable role
in achieving the semantic interoperability for the secondary use of
EHR among multiple sites.
4.2. Improving future research on the natural history of long COVID
All published studies analyzed in this work present their results in
aggregate rather than providing row level data for each participant.
This prevents most data reuse to analyze correlations between
comorbidities and risk for long COVID or for specific manifestations
of long COVID, and this makes it impossible to investigate potential
correlations between long COVID manifestations. Therefore, future
studies should present non-identifiable information about individual
patients. This will allow correlations between variables. Also, studies
need to use controlled vocabulary to classify patients and need to
agree on a minimal set of information. Presenting (non-identifiable)
data in the form of a table with one row per patient would be a great
improvement over the current status. More sophisticated strategies
for recording individual clinical histories are available, such as the
Global Alliance for Genomics and Health phenopacket schema [43].
The majority of studies included in this analysis did not apply
inclusion criteria to correspond to any specific definition of long
COVID, but instead studied groups of patients who had previously
undergone infection by SARS-CoV-2 with a range of manifestations in
the acute phase. Long COVID can be broadly defined as delayed
recovery from an episode of COVID-19 and is characterised by lasting
effects of the infection, e.g., persistence of symptoms or onset of new
chronic diseases, for longer than would be expected [8]. Although no
firm criteria have been established to define the post-acute period or
sub-categories within long COVID, several sets of guidelines have
been proposed for the classification of COVID-19-related disease phe-
notypes, and these criteria were compared to the definitions used in
the literature. For example, a recently proposed public health frame-
work classifies SARS-CoV-2-related disease into three categories [44].
The first is acute COVID-19, or the disease most commonly associated
with acute SARS-CoV-2 infection. The second category includes Mul-
tisystem Inflammatory Syndrome in Children (MIS-C) and in adults
(MIS-A), a less common presentation of SARS-CoV-2 infection charac-
terised by hyperinflammation that can appear 4-6 weeks after viral
infection [45]. The third category describes late sequelae [44]. In
terms of defining study cohorts, adherence with this definition would
require a clinical diagnosis, rather than a SARS-CoV-2 test alone, to
distinguish MIS-C/A and COVID-19. While it appears too early to pro-
pose a set of computable definitions for the various types of disease
associated with SARS-CoV-2 (because we are still learning about the
natural history), it would be advantageous for studies to apply a cur-
rently accepted definition of long COVID and to describe details in
the methods. Studies should denote comorbidities using a standard
ontology of diseases such as Mondo [46].
Additionally, in many cases it is difficult to know if a clinical
abnormality was present prior to acute COVID-19 and was merely
diagnosed by investigations and additional clinical tests that were
performed following the diagnosis of COVID-19. For instance, Hepatic
steatosis was reported to be more common in individuals following
acute COVID-19 infection in a single study [47]. However, this is a
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common finding in the general population and additional research
will be required to characterise its precise relation to long COVID.
The studies analyzed in this work varied widely in the terminology
used to describe patient-reported symptoms as well as clinical signs,
laboratory abnormalities, and imaging findings. For example, the stud-
ies analyzed included a mixture of reports of ageusia [48,49], anosmia
[48,49], anosmia/ageusia [50], loss of smell [51,52], loss of taste [51],
loss of smell and taste [53], loss of smell or taste [54], and loss of smell
and/or taste [55]. While in many cases there are parallels among stud-
ies (e.g., studies reporting anosmia and loss of smell are likely to be
asking the same or similar questions of patients), the lack of a strict
definition prevents straight-forward symptom matching across multi-
ple published analyses. Different studies measure clinical manifesta-
tions in different ways. For instance, the presence of fatigue can be
measured by a yes/no question in an online questionnaire or can be
inferred from the results of a multidimensional study instrument such
as the Short Form-36 Vitality scale [56]. In such cases, standard use of
a full terminology such as HPO would be useful to create expressive
and consistent meaning across studies. Future studies should make
data available using either the HPO terms provided here or other terms
from the full collection of over 16,000 HPO terms.
From a clinical standpoint our work demonstrates that managing
long COVID patients will require a multidisciplinary effort. Given that
respiratory system findings and fatigue were the most common, a
pulmonologist with a pulmonary rehabilitation program will be one
of the cornerstones of any long COVID management program. At the
same time considering the high frequency of psychiatric and neuro-
logical symptoms, psychiatrists and neurologists with specialization
in neurocognitive testing and treatment will be necessary. Further-
more given the extreme variation in symptoms and presentation, a
primary care internist will have to be responsible for coordinating
the care of long COVID patients with appropriate referrals when
required. Taking into account the high frequency of long COVID in
survivors primary care physicians will have to be made aware of the
myriad presentations of long COVID with active screening for long
COVID. Primary care physicians will need to refer long COVID
patients to dedicated long COVID management programs.
Working toward computable long COVID phenotypes in this way
will improve our ability to understand the natural history of long
COVID. Such phenotypes will also allow observational analyses of fac-
tors that may reduce long COVID symptoms. The standardised phe-
notypic features and synonyms bundled in the HPO terms presented
here are a foundation for natural language processing of EHR data,
clinical decision support tools, and analytic approaches such as
machine learning.
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